Results 1 to 10 of about 5,425 (150)

Clinical Implication of the Antidiuretic Hormone (ADH) Receptor Antagonist Mozavaptan Hydrochloride in Patients with Ectopic ADH Syndrome [PDF]

Japanese Journal of Clinical Oncology, 2010
Ectopic antidiuretic hormone syndrome is a medical emergency characterized by dilutional hyponatremia. Clinical effectiveness of the vasopressin V2 receptor antagonist mozavaptan was evaluated in 16 patients. In short-term (7-day) treatment with the drug, serum sodium concentration (mean ± standard deviation) significantly (P = 0.002) increased from ...
Ken, Yamaguchi, Noriharu, Shijubo, Tetsuro, Kodama, Kiyoshi, Mori, Takahiko, Sugiura, Takayuki, Kuriyama, Masaaki, Kawahara, Tetsu, Shinkai, Haruo, Iguchi, Masanori, Sakurai   +9 more
openaire   +3 more sources

Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice

Endocrine Journal, 2012
Hyponatraemia (serum sodium ...
Rajendran, R, Grossman, AB, Kar, P
openaire   +4 more sources

Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide Vasopressin V2-Receptor Antagonist [PDF]

Clinical Journal of the American Society of Nephrology, 2006
The effects of satavaptan (SR121463B), a novel long-acting orally active vasopressin V(2)-receptor antagonist, were investigated in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). In the first part of this randomized, double-blind study, 34 patients first were treated with satavaptan (versus placebo) for up to 5 d ...
Alain, Soupart, Peter, Gross, Jean-Jacques, Legros, Sándor, Alföldi, Djillali, Annane, Hassan M, Heshmati, Guy, Decaux   +6 more
openaire   +3 more sources

A Novel Vasopressin Dual V1A/V2 Receptor Antagonist, Conivaptan Hydrochloride, Improves Hyponatremia in Rats with Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH)

Biological and Pharmaceutical Bulletin, 2007
We investigated the effects of intravenous administration of conivaptan hydrochloride, a dual vasopressin V1A and V2 receptor antagonist, on blood electrolytes and plasma osmolality in rats with an experimental syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Koh-ichi, Wada, Utane, Matsukawa, Akira, Fujimori, Yukinori, Arai, Katsumi, Sudoh, Masao, Sasamata, Keiji, Miyata   +6 more
openaire   +4 more sources

Syndrome of Inappropriate Secretion of Antidiuretic Hormone in a Dog With Meningoencephalitis of Unknown Etiology. [PDF]

Vet Med Sci
This report describes a case of syndrome of inappropriate antidiuretic hormone secretion (SIADH) in a Maltese with meningoencephalitis of unknown etiology (MUE). The dog was treated with water restriction and tolvaptan, a vasopressin receptor antagonist, which resulted in an improvement in hyponatremia.
Lee Y, Park J, Chae Y, Yun T, Kim H, Kang BT.   +5 more
europepmc   +2 more sources

Vasopressin and a Nonpeptide Antidiuretic Hormone Receptor Antagonist (OPC-31260)

Blood Pressure, 1994
The development of nonpeptide orally active AVP analogues has provided a new tool with which to assess the physiological and pathophysiological role of vasopressin (AVP). We have previously characterised the nonpeptide vasopressin V1 receptor antagonist OPC-21268, and now report the in vitro characterisation of the nonpeptide V2 receptor antagonist OPC-
L M, Burrell, P A, Phillips, J M, Stephenson, J, Risvanis, C I, Johnston   +4 more
openaire   +3 more sources

Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

European Journal of Clinical Pharmacology, 2011
Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of V(1a)R-mediated vasoconstriction and V(2)R-induced water retention represent a potentially attractive target of therapy for edematous diseases.
Gassanov, Natig, Semmo, Nasser, Semmo, Mariam, Nia, Amir M., Fuhr, Uwe, Er, Fikret   +5 more
openaire   +5 more sources

Evaluation of the Effect of IL-1 Antagonists on Pituitary Function. [PDF]

Int J Endocrinol
Background Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease frequently observed in populations along the Eastern Mediterranean coast, characterized by recurrent fever, abdominal pain, and joint inflammation. The disease results from mutations in the MEFV gene, which plays a critical role in regulating IL‐1β secretion ...
Aktas Koc F, Sariakcali B, Sahin A.
europepmc   +2 more sources

Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database [PDF]

Scientific Reports
Background NK-1 receptor antagonists (NK-1RAs) are proven to be successful in preventing chemotherapy-induced nausea and vomiting (CINV). The safety profile of NK-1RAs has not been systematically analyzed in the real world.
Hong Pan, Xiang Shi, Yiguo Jiang, Jiaqiang Wu, Li Shen   +4 more
doaj   +2 more sources

A Case of Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Selpercatinib in a Patient With RET Fusion Gene-Positive Non-Small Cell Lung Cancer. [PDF]

Respirol Case Rep
We report a case of selpercatinib‐induced syndrome of inappropriate secretion of antidiuretic hormone (SIADH) that improved after drug withdrawal and was safely resumed at a reduced dose. ABSTRACT An 80‐year‐old woman with a lung nodule in the right lower lobe and pleural thickening was diagnosed with lung adenocarcinoma by a surgical lung biopsy.
Tanaka Y, Ikegami N, Miyamoto K, Shingu Y, Okagaki N, Sakamoto H, Nakanishi T, Nakamura S, Matsumura K, Ueyama M, Kaji Y, Hashimoto S, Tanaka E, Taguchi Y, Ohsumi Y, Nakagawa T, Matsunaga S, Hajiro T.   +17 more
europepmc   +2 more sources